Literature DB >> 28643790

Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.

Niclas E Bengtsson, John K Hall, Guy L Odom, Michael P Phelps, Colin R Andrus, R David Hawkins, Stephen D Hauschka, Joel R Chamberlain, Jeffrey S Chamberlain.   

Abstract

This corrects the article DOI: 10.1038/ncomms14454.

Entities:  

Year:  2017        PMID： 28643790      PMCID： PMC5489999          DOI： 10.1038/ncomms16007

Source DB:  PubMed          Journal:  Nat Commun        ISSN： 2041-1723            Impact factor:   14.919


This Article contains an error in Fig. 4, for which we apologize. In panel a, the image reporting dystrophin labelling following SaCas9Δ5253 treatment was inadvertently duplicated from the corresponding image following SpCas9/Δ5253 treatment. The correct version of this figure appears below as Fig. 1. The raw data associated with this experiment are provided as a separate Supplementary Data file.
Figure 1
  14 in total

Review 1.  Gene therapies in canine models for Duchenne muscular dystrophy.

Authors:  Peter P Nghiem; Joe N Kornegay
Journal:  Hum Genet       Date:  2019-02-07       Impact factor: 4.132

Review 2.  Stem cell-based therapies for Duchenne muscular dystrophy.

Authors:  Congshan Sun; Carlo Serra; Gabsang Lee; Kathryn R Wagner
Journal:  Exp Neurol       Date:  2019-10-19       Impact factor: 5.330

3.  Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model.

Authors:  Niclas E Bengtsson; Julie M Crudele; Jordan M Klaiman; Christine L Halbert; Stephen D Hauschka; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2022-02-08       Impact factor: 12.910

4.  DMD carrier model with mosaic dystrophin expression in the heart reveals complex vulnerability to myocardial injury.

Authors:  Tatyana A Meyers; Jackie A Heitzman; DeWayne Townsend
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

5.  Immunogenicity of Cas9 Protein.

Authors:  Aditi Mehta; Olivia M Merkel
Journal:  J Pharm Sci       Date:  2019-10-04       Impact factor: 3.534

Review 6.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

Review 7.  (Epi)genetic Modifications in Myogenic Stem Cells: From Novel Insights to Therapeutic Perspectives.

Authors:  Natacha Breuls; Giorgia Giacomazzi; Maurilio Sampaolesi
Journal:  Cells       Date:  2019-05-09       Impact factor: 6.600

Review 8.  Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.

Authors:  Tatyana A Meyers; DeWayne Townsend
Journal:  Int J Mol Sci       Date:  2019-08-22       Impact factor: 5.923

9.  AAV-Mediated Gene Transfer Restores a Normal Muscle Transcriptome in a Canine Model of X-Linked Myotubular Myopathy.

Authors:  Jean-Baptiste Dupont; Jianjun Guo; Edith Renaud-Gabardos; Karine Poulard; Virginie Latournerie; Michael W Lawlor; Robert W Grange; John T Gray; Ana Buj-Bello; Martin K Childers; David L Mack
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

10.  In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse.

Authors:  Leonela Amoasii; Hui Li; Yu Zhang; Yi-Li Min; Efrain Sanchez-Ortiz; John M Shelton; Chengzu Long; Alex A Mireault; Samadrita Bhattacharyya; John R McAnally; Rhonda Bassel-Duby; Eric N Olson
Journal:  Nat Commun       Date:  2019-10-04       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.